FDA Issues Final Artificial Pancreas Guidance

The U.S. Food and Drug Administration (FDA) announced on November 9 the issuance of its final guidance for the development of artificial pancreas systems. The guidance incorporates nearly all of JDRF’s recommendations. This news represents a milestone victory for JDRF and the type 1 diabetes (T1D) community, as the technology is viewed by medical experts […]

FDA Approves Lucentis to Treat Diabetic Macular Edema

For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis for the treatment of DME. Developed by Genentech, Lucentis is the first and only FDA-approved medicine for the condition. Diabetic macular edema […]

JDRF Discusses New Treatment for Diabetic Eye Disease

Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).

Combination Therapy May Help in Islet Transplant Failure

Researchers at the University of Alberta have reported that a two-drug combination, sitagliptin and pantoprazole, can restore insulin independence in some islet transplant recipients with early signs of transplant failure. The effect was not sustained after withdrawal of the drugs; there was lack of evidence for durable effects on beta cell function or increased beta cell mass. JDRF continues to support research to improve long-term islet transplant function and to promote beta cell regeneration in all people with T1D.

50-Year Medalist Study Shows Positive Results

In the JDRF-funded Medalist Study of individuals who have lived with T1D for at least 50 years, researchers have discovered that some Medalists are protected from advanced diabetic retinopathy because they have a slow rate of retinopathy onset or progression. Further, after 20 years of T1D, progression of retinopathy appears to halt. Researchers can now search for factors that mediate this slow disease progression and exploit them to develop new strategies to prevent or treat diabetic retinopathy.

Progress in Testing Artificial Pancreas Systems in Clinical and Real-World Settings

A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.

Researchers Formulate Stable Liquid Glucagon

JDRF-funded researchers have developed a formulation of liquid glucagon that remains stable and viable for long periods of time and thus may be usable in standard diabetes pumps. The research represents advancement toward the routine delivery of glucagon for people with T1D and may also facilitate the development of bihormonal closed-loop artificial pancreas systems.

Research Summit: Transforming JDRF

JDRF executives and 110 JDRF donors gathered in sunny St. Petersburg, FL, on May 1 and 2 for the JDRF Research Summit: Transforming JDRF. Attendees, including generous donors and dedicated volunteers from Florida and the surrounding states—as well as some from as far away as California—received a “crash course” in exactly what’s happening in the […]

For Your Attention: The Special Diabetes Program

The Special Diabetes Program (SDP) of the National Institutes of Health was established in 1997. The SDP is a key component of the federal government’s commitment to type 1 diabetes (T1D) research. There are two parts of the program: the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians. In the […]